FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Shizhi ^a   Wu, Shenshen ^a   Meng, Qingtao ^a   Li, Xiaobo ^a   Zhang, Jinchun ^b   Chen, Rui ^a   Wang, Meilin ^c,d  

^a SOUTHEAST UNIVERSITY   (China)

^b Nanjing Municipal Hospital of TCM   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Nanjing Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN; FAS ANTIGEN; FAS LIGAND; PROTEIN BINDING; STAT1 PROTEIN; TRANSCRIPTION FACTOR SP1;

ALLELE; CASE CONTROL STUDY; CHROMATIN; COLORECTAL TUMOR; DISEASE COURSE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ANTIGENS, CD95; CASE-CONTROL STUDIES; CHROMATIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FAS LIGAND PROTEIN; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RISK; SP1 TRANSCRIPTION FACTOR; STAT1 TRANSCRIPTION FACTOR;

EID: 84954505134     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19229     Document Type: Article

References (38)

1. Brenner, H., Kloor, M. and Pox, C. P. Colorectal cancer. Lancet 383, 1490-1502 (2014).
2. Peters, U., Bien, S. and Zubair, N. Genetic architecture of colorectal cancer. Gut 64, 1623-1636 (2015).
3. Bardhan, K. and Liu, K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) 5, 676-713 (2013).
4. Ng, J. M. and Yu, J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci 16, 2472-2496 (2015).
5. Colussi, D., Brandi, G., Bazzoli, F. and Ricciardiello, L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14, 16365-16385 (2013).
6. Yang, S. Y., Sales, K. M., Fuller, B., Seifalian, A. M. and Winslet, M. C. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 15, 225-233 (2009).
7. Mehlen, P. and Tauszig-Delamasure, S. Dependence receptors and colorectal cancer. Gut 63, 1821-1829 (2014).
8. Hoogwater, F. J., Steller, E. J., Westendorp, B. F., Borel Rinkes, I. H. and Kranenburg, O. CD95 signaling in colorectal cancer. Biochim Biophys Acta 1826, 189-198 (2012).
9. Ashkenazi, A. and Salvesen, G. Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol 30, 337-356 (2014).
10. Lee, W., Yue, P. and Zhang, Z. Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet 126, 481-498 (2009).
11. Wang, M. et al. Genetic variant in APE1 gene promoter contributes to cervical cancer risk. Am J Obstet Gynecol 209, 360 e361-367 (2013).
12. Huang, Q. R., Morris, D. and Manolios, N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34, 577-582 (1997).
13. Sibley, K. et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63, 4327-4330 (2003).
14. Wu, J. et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170, 132-138 (2003).
15. Sun, T. et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96, 1030-1036 (2004).
16. Zhao, H., Zheng, L., Li, X. and Wang, L. FasL gene - 844T/C mutation of esophageal cancer in South China and its clinical significance. Sci Rep 4, 3866 (2014).
17. Zhang, Z. et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12, 5596-5602 (2006).
18. Li, C. et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 16, 245-251 (2006).
19. Wang, M. et al. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China. Biochem Genet 47, 559-568 (2009).
20. Du, H. et al. Association study between XPG Asp1104 His polymorphism and colorectal cancer risk in a Chinese population. Sci Rep 4, 6700 (2014).
21. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525-532 (1988).
22. Kinzler, K. W. and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
23. Fouque, A., Debure, L. and Legembre, P. The CD95/CD95L signaling pathway: a role in carcinogenesis. Biochim Biophys Acta 1846, 130-141 (2014).
24. Peyvandi, S. et al. Fas Ligand Deficiency Impairs Tumor Immunity by Promoting an Accumulation of Monocytic Myeloid-Derived Suppressor Cells. Cancer Res 75, 4292-4301 (2015).
25. Liu, F. et al. NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 287, 25530-25540 (2012).
26. Gajate, C. and Mollinedo, F. Lipid raft-mediated Fas/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications. J Leukoc Biol 98, 739-759 (2015).
27. Chen, Y. et al. Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis. Int J Clin Exp Med 8, 3817-3824 (2015).
28. Gu, D. et al. Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer. Environ Mol Mutagen 55, 421-427 (2014).
29. Yang, S. et al. [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer]. Zhonghua Yi Xue Za Zhi 85, 2132-2135 (2005).
30. Xu, Y. et al. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies. PLoS One 9, e90090 (2014).
31. Du, Y., Hu, L. and Pan, Y. Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis. Biomed Rep 1, 269-274 (2013).
32. Yuan, H. P., Liu, Q. D., Li, G. Q. and Cong, Y. Q. Fas - 670A/G (rs1800682) polymorphism and digestive cancer risk in Asians: a metaanalysis. Genet Test Mol Biomarkers 18, 482-488 (2014).
33. Look, D. C., Pelletier, M. R., Tidwell, R. M., Roswit, W. T. and Holtzman, M. J. Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 270, 30264-30267 (1995).
34. Ogino, S. and Stampfer, M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 102, 365-367 (2010).
35. Ogino, S., Chan, A. T., Fuchs, C. S. and Giovannucci, E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60, 397-411 (2011).
36. Ogino, S. and Giovannucci, E. Commentary: Lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol 41, 1072-1074 (2012).
37. Ogino, S. et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol 176, 659-667 (2012).
38. Schulz, K. F., Altman, D. G., Moher, D. and Group, C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7, e1000251 (2010).